BALTIMORE - Marylandian -- Baltimore, MD - Dr. George Laliotis, a distinguished physician-scientist, has led a groundbreaking study that could revolutionize the way we approach cancer treatment. His team has discovered that simple blood tests could accurately predict the effectiveness of immunotherapy in patients suffering from head and neck squamous cell carcinoma (HNSCC).

Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has been a game-changer in cancer treatment. However, only a small percentage of patients respond to the treatment, and it often comes with severe side effects. Moreover, the assessment of genetic and molecular predictive factors is expensive and time-consuming.

Dr. Laliotis and his team have identified new predictive factors that can quickly, affordably, and accurately measure the response of HNSCC patients to immunotherapy. This discovery could lead to improved clinical care in medical oncology and a significant step towards personalized medicine.

More on Marylandian

• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)

The team's research proposes straightforward predictive tools obtained from a standard blood draw. These tools measure red blood cells, platelets, lactate dehydrogenase (LDH), hemoglobin, and albumin levels. Combined with basic epidemiological variables and additional clinical criteria, these tools could predict the response of HNSCC patients to ICI treatment.

The researchers demonstrated that these factors are strong predictors of clinical outcomes. They collected data from a sample of 200 patients treated with a single-agent PD-1 inhibitor and monitored for a short follow-up period of four years. The results conclusively found that these factors are strong predictors of the clinical outcomes of these patients.

This breakthrough discovery of precision-medicine markers through cheap and widely available tools means cancer treatment could be more precisely tailored to the needs of each patient, improving patient outcomes. Moreover, it's an accessible and affordable approach that could be adopted by healthcare systems worldwide.

Dr. Laliotis and his team are among the first to show how commonly used clinical techniques, like taking blood samples and looking at a patient's clinical history, can help clinicians predict how HNSCC patients will respond to immunotherapy. This breakthrough discovery of precision-medicine markers through cheap and widely available tools means cancer treatment could be more precisely tailored to the needs of each patient, improving patient outcomes. Moreover, it's an accessible and affordable approach that could be adopted by healthcare systems worldwide.

More on Marylandian

• Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
• Community Reintroduction & Rebranding Announcement
• Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
• The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
• $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD

For more information about Dr. George Laliotis and his research, please visit georgelaliotis.com.

The full details of the study can be found at Research Outreach.

About Dr. George Laliotis

Dr. George Laliotis is a physician and scientist. With a decade of experience in clinical, medical affairs, and research, George is dedicated to advancing his knowledge and skills to improve patient care.

George Laliotis
Website: georgelaliotis.com
Linkedin: www.linkedin.com/in/george-laliotis-56850779
Twitter: https://twitter.com/Geor_Laliot